Palmar-plantar erythrodysesthesia

Arjun Gupta, Anurag Mehta, Sahil Khanna

1University of Texas Southwestern Medical Center, Dallas, Texas, USA
2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA

Correspondence to Dr Sahil Khanna, khanna.sahil@mayo.edu

Accepted 23 August 2015

DESCRIPTION

A 59-year-old woman presented with pain, tingling and desquamation over bilateral palms and soles for 4 weeks, associated with inability to perform activities of daily living (ADL). She had received 5-fluorouracil, bevacizumab and irinotecan for metastatic colon cancer 6 weeks earlier. Examination revealed diffuse hyperpigmentation and blisters on palms and soles, and an ulcer over the right plantar surface (figures 1 and 2). A clinical diagnosis of grade 3 palmar-plantar erythrodysesthesia (PPE) was made, and she was treated with topical emollients. Chemotherapy was held and she ultimately opted for hospice care.

This report is targeted for general practitioners, internists and emergency room physicians who may not encounter PPE often. PPE, or chemotherapy-associated acral erythema, is a cutaneous toxicity syndrome traditionally associated with cytotoxic chemotherapy agents (5-fluorouracil, docetaxel, cytarabine, liposomal doxorubicin, capcitabine); however, it is increasingly being associated with use of molecular agents (sorafenib, sunitinib, axitinib, pazopanib). Incidence, which was traditionally in the 10% range, has shot up and may be as high as 62% in patients treated with sorafenib.1 Symptoms include dysesthesia and tingling, progressing to pain and swelling, blistering, desquamation and ulceration. Severity is graded per the Common Terminology Criteria for Adverse Events (CTCAE) V.4, with grade 3 reflecting severe skin changes and difficulty performing self-care ADL (table 1).2 The pathogenesis is incompletely understood, but direct chemotherapy toxicity due to leakage into the capillary bed is a potential mechanism. Higher cumulative dose and sustained serum levels of cytotoxic drugs are more frequently associated with PPE occurrence.3 Differential diagnoses include erythromelalgia, graft-versus-host disease and Raynaud’s disease. Patients with grade 1 PPE are managed symptomatically and severe PPE (grade 2 or 3) needs dose reduction in chemotherapy or a switch to an alternative regimen (if available) to avoid recurrence. Preventive strategies include avoiding contact of hands and feet with heat (sunburn and saunas) and chemicals (household cleaning), and reducing frictional contact (occupational or recreational). Vigilance and reporting early symptoms may halt progression of the condition. There are no proven therapeutic treatments but emollients (urea), moisturisers, ice packs and cooling therapy, vitamin B6 supplementation and pain relief with non-steroidal anti-inflammatory drugs may provide symptomatic relief.

Table 1 CTCAE V.4, guidelines reflecting the severity of palmar-plantar erythrodysesthesia

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Grade 0</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmar-plantar erythrodysesthesia syndrome</td>
<td>No symptoms</td>
<td>Minimal skin changes or dermatitis (eg, erythema, oedema, or hyperkeratosis) without pain</td>
<td>Skin changes (eg, peeling, blisters, bleeding, oedema, or hyperkeratosis) with pain; limiting instrumental ADL</td>
<td>Severe skin changes (eg, peeling, blisters, bleeding, oedema, or hyperkeratosis) with pain; limiting self-care ADL</td>
</tr>
</tbody>
</table>

*Note there are no grade 4 or 5 CTCAE criteria for palmar-plantar erythrodysesthesia. ADL, activities of daily living; CTCAE, Common Terminology Criteria for Adverse Events.
Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Learning points

- Palmar-plantar erythrodysesthesia is a debilitating complication of some commonly used chemotherapeutic agents.
- Patients with grade 2 or 3 palmar-plantar erythrodysesthesia require dose reduction or an alternative chemotherapy regimen to avoid recurrence.

REFERENCES

1 Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia); focus on sorafenib and sunitinib. *Oncology* 2009;77:257–71.
2 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf

Copyright 2015 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit http://group.bmj.com/group/rights-licensing/permissions.

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- Submit as many cases as you like
- Enjoy fast sympathetic peer review and rapid publication of accepted articles
- Access all the published articles
- Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow.